Sorrento Shares Gain Following FDA's Nod for Initial-Stage Covid-19 Study

Sorrento Therapeutics SRNE announced that the U.S. Food and Drug Administration (FDA) has cleared the Phase 1 study of its candidate, STI-1558, in patients with impaired renal and hepatic function.

STI-1558 is an oral SARS-CoV-2 main protease inhibitor which can block viral replication, is specifically designed as a standalone treatment of COVID-19.

The Phase 1 study cleared by the FDA is designed to examine the pharmacokinetic (PK) in patients with moderate renal and hepatic impairment.

Two doses of STI-1558 (300 mg and 600 mg) will be studied in 12 subjects across 3 cohorts, 12 normal subjects, 12 renally-impaired subjects and 12 hepatically-impaired subjects, using a cross-over design.

The ongoing Phase 1 Study of STI-1558 evaluating single ascending doses (SAD), multiple ascending doses (MAD) and food effect is proceeding in Australia, and the drug has been dosed in patients in the first 3 cohorts with doses of 300, 600 and 1,200 mg.

Henry Ji, Chairman, President and CEO, commented : "STI-1558 has the potential to be a highly effective antiviral treatment for acute COVID-19 and we look forward to seeing how it performs in the Phase 1 study and the planned Phase 2/3 study.”

Price Action : Sorrento shares are trading around 8 percent higher at $2.67 on Tuesday at the time of publishing.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMovers & ShakersSmall CapFDAGeneralFDA IND Clearance
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!